Shares of Moderna Inc. MRNA,
they fell 0.1% in pre-trade on Friday after the company said the European Commission plans to buy an additional 80 million doses of its COVID-19 vaccine candidate. The commission had previously made an agreement for 80 million doses. Moderna’s still-research vaccine requires two doses for each person, separated by one month. It has not yet been approved or authorized in any country; however, an emergency use authorization from the Food and Drug Administration is expected at any time. European Union health officials are expected to decide whether to grant a conditional marketing authorization for the vaccine on 6 January. Moderna’s stock has risen 636.2% so far this year, while the S&P 500 SPX,
increases by 15.2%.